Andrew F Alexis, MD, MPH

Significance of ADmirable Data on Lebrikizumab Use for Atopic Dermatitis in Skin of Color

2025 Revolutionizing Atopic Dermatitis (RAD) Conference

 team spoke with a trial investigator from the phase 3b ADmirable study about the impact of lebrikizumab (Ebglyss) on atopic dermatitis in adult and adolescent patients with skin of color.

The team interviewed Andrew Alexis, MD, MPH, an ADmirable investigator, professor of clinical dermatology, and vice-chair for diversity and inclusion at Weill Cornell Medicine, on the 

 and its significance for those with atopic dermatitis who are also patients with skin of color. Alexis was asked how he sees the ADmirable data contributing to the broader effort to improve diagnosis, treatment, and representation in atopic dermatitis care for patients with skin of color.

Alexis noted that he believes the data contribute to the overall understanding of atopic dermatitis across diverse patient populations, adding that they help to fill a historic data gap with respect to patients with skin of color. In addition, Alexis highlighted that there were many clinical photos that were taken as part of the study, which in turn could serve as educational tools and give us even further insight into the variable morphology of atopic dermatitis across different time points.

Alexis has reported advisory/consulting fees from companies including Lilly.

Alexis A, Moiin A, Waibel J, et al. Efficacy and safety of lebrikizumab in adult and adolescent patients with skin of color and moderate-to-severe atopic dermatitis: final 24-wWeek results from the phase 3b, open-label ADmirable study. Presented at: 2025 Revolutionizing Atopic Dermatitis (RAD) Conference; June 6-7, 2025; Nashville, TN.

FDA Approves Lilly's EBGLYSS™ (lebrikizumab-lbkz) for Adults and Children 12 Years and Older with Moderate-to-Severe Atopic Dermatitis. September 13, 2024. Accessed June 18, 2025. 

https://investor.lilly.com/news-releases/news-release-details/fda-approves-lillys-ebglysstm-lebrikizumab-lbkz-adults-and

Videos

This interview with Andrew Alexis, MD, MPH, highlights his team’s findings in the phase 3b ADmirable trial on lebrikizumab for atopic dermatitis in patients with skin of color.

Discussing Significance of Delayed Response to Lebrikizumab in Initial Nonresponders 

An interview was conducted following the release of new data at the 

 on the impact of of lebrikizumab (Ebglyss) on atopic dermatitis in adult and adolescent patients with skin of color. The 

 editorial team spoke with Andrew Alexis, MD, MPH, ADmirable investigator, professor of clinical dermatology, and vice-chair for diversity and inclusion at Weill Cornell Medicine, about the new phase 3b findings on lebrikizumab in atopic dermatitis for patients with skin of color.

The study’s main efficacy measure had been 75% or greater improvement in patients’ Eczema Area and Severity Index (EASI) scores. EASI-75 response rates were noted by the investigators as having increased through Week 24, particularly in participants with skin phototype VI. Alexis highlighted that in a cohort of subjects who were considered non-responders at Week 16, when these patients remained on treatment with lebrikizumab every 2 weeks, almost half of them went on to be responders at the 24-week mark.

Given this substantial proportion of initial nonresponders achievement of response with continued Q2W dosing, Alexis highlighted what might this suggest about persistence with therapy when treating patients who do not respond to lebrikizumab treatment early.

Significance of EASI-75 Response Rates in Patients with Skin of Color on Lebrikizumab

new phase 3b findings on lebrikizumab (Ebglyss)

 treatment of atopic dermatitis in adult and adolescent patients with skin of color, 

 interviewed Andrew Alexis, MD, MPH, ADmirable study investigator, professor of clinical dermatology, and vice-chair for diversity and inclusion at Weill Cornell Medicine.

The trial’s primary efficacy measure had been 75% or greater improvement in the Eczema Area and Severity Index (EASI). Participants in the ADmirable analysis had Fitzpatrick skin phototypes IV, V, or VI and self-identified as a race other than White. EASI-75 response rates were shown to have increased through Week 24, particularly in patients with skin phototype VI. Alexis was asked how this informs expectations around response kinetics or treatment duration in patients with skin of color.

Alexis noted that response rates had been strong at Week 16. He added that in a cohort of patients who were considered non-responders at Week 16, when these patients remained on treatment with lebrikizumab every 2 weeks, almost half of them went on to become responders by the 24-week mark.

Effects of Lebrikizumab on Post-Inflammatory Hyperpigmentation in Skin of Color

Following the release of new findings presented at the 

Revolutionizing Atopic Dermatitis (RAD) Conference

 on the impact of of lebrikizumab (Ebglyss) on atopic dermatitis in adult and adolescent patients with skin of color, the 

 team spoke with Andrew Alexis, MD, MPH, ADmirable investigator, professor of clinical dermatology, and vice-chair for diversity and inclusion at Weill Cornell Medicine.

During the 90-participant, phase 3b ADmirable study, those included had Fitzpatrick skin phototypes IV, V, or VI and self-identified as a race other than White. The trial’s primary efficacy measure had been 75% or greater improvement in the Eczema Area and Severity Index (EASI) at the 16-week mark and, in secondary and exploratory outcomes, Alexis and coauthors had looked at the recently developed PDCA Derm scale, a measure of post-inflammatory hyper- and hypopigmentation and safety data.

 about the PDCA-Derm findings that had indicated improvement in post-inflammatory hyperpigmentation in nearly 2-thirds of patients. He highlighted the significance of these findings and how it aligns with what clinicians should consider when addressing pigmentary sequelae in patients of color.

Andrew F Alexis, MD, MPH

Articles